We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.232 | 3.15% | 7.592 | 7.58 | 7.60 | 7.674 | 7.54 | 7.64 | 476,811 | 15:29:24 |
From May 2021 to May 2024
By Chris Wack
Evotec SE on Friday said Bayer AG is discontinuing the development of the investigational P2X3 receptor antagonist eliapixant, which stems from a former joint company multitarget research alliance.
Evotec said that following a review of the available data, Bayer concluded the overall benefit no longer outweighs the risk in the actively pursued indications.
Evotec said it regains the rights to all P2X3 assets. The company said it will evaluate the underlying data once available and consider all options.
Evotec shares fell 10% to $18.50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 04, 2022 08:22 ET (13:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
